Why Is SUPERNUS PHARMACEUTI (SUPN) Stock Up Today?
By the Top Tier Newswire AI Desk · August 3, 2026 at 10:59 AM ET · reviewed against 16 wire stories
SUPERNUS PHARMACEUTI (SUPN) is up +9.69% in the latest session. Our newswire has captured 16 stories on SUPN across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SUPN stock is up today
Supernus Pharmaceuticals shares surged 9.69% to $48.95 in early trading after the company announced a proposed tax-free merger of equals with Indivior. The deal is expected to create a $2.2 billion central nervous system (CNS) biopharmaceutical leader and unlock $125 million in annual cost synergies. The merger announcement came alongside Supernus’s second-quarter financial results, which included a revenue beat and raised 2026 guidance despite an earnings miss due to a non-cash impairment charge.
What Happened
Supernus and Indivior announced a stock-for-stock merger that will combine their neuroscience drug portfolios and create a larger, more diversified biopharmaceutical company. The deal is structured as a merger of equals, with Supernus shareholders receiving 1.5401 shares of Indivior per share of Supernus. Indivior shareholders will also receive a one-time special cash dividend of $1 billion immediately prior to the closing of the transaction. The companies highlighted the potential for significant cost synergies and immediate scale, which has generated optimism among investors.
The merger was announced following Supernus’s second-quarter earnings report. While the company reported a net loss, it beat revenue estimates and raised its full-year guidance. Indivior also reported record-breaking second-quarter results, with 111% year-over-year EBITDA growth, further supporting the strategic rationale for the merger.
What The Data Shows
The stock opened with a 24.4% gap up at $55.50, reaching a session high of $57.20 before retreating to close the session at $48.88. The intraday volume of 1.5 million shares is 2.1 times the 3-month average, indicating strong investor interest. Over the last 8 sessions, the stock had declined 4.9% from $46.94 to $44.63, making the current move a significant reversal. Supernus has a market cap of $2.6 billion, but remains unprofitable with a trailing twelve-month EPS of -0.51 and a net margin of -3.7%.
What To Watch
The merger is expected to close in the near term, though no specific date has been provided. Investors will want to monitor the progress of the transaction and any regulatory developments. Additionally, Supernus is scheduled to release further updates on its strategic initiatives and financial performance in the coming quarters.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SUPN · Aug 3 session (5-min) · +3.07% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 16 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7d agoMarketChameleonBULLISH 65M&A
SUPN and Indivior to Merge: $2.2 Billion CNS Giant to Unlock $125 Million in Annual Cost Synergies
Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces, forming a $2.2 billion diversified CNS biopharmaceutical leader. The deal, structured as a merger of equals, promises immediate scale, $125 million in annual cost savings, and a robust platform for long-term growth and innovation.
7d agoYahoo FinanceBULLISH 65M&A
Indivior Q2 Earnings Call Highlights
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The t
7d agoTipRanksBULLISH 55M&A
Supernus and Indivior Announce Proposed Stock-for-Stock Merger
Supernus Pharmaceuticals ( ($SUPN) ) has shared an update. On August 3, 2026, Supernus Pharmaceuticals and Indivior Pharmaceuticals held a joint conference call and...
7d agoTipRanksBULLISH 55M&A
Indivior and Supernus announce tax-free merger of equals
The latest announcement is out from Indivior ( ($INDV) ). Indivior Pharmaceuticals, Inc. is a biopharmaceutical company focused on central nervous system disorders,...
7d agoInvestorsHubBULLISH 73M&A
Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement
Supernus beat second-quarter revenue estimates, raised its 2026 guidance and announced a merger with Indivior, sending shares sharply higher despite an earnings miss driven by a non-cash impairment charge.
7d agoMarketChameleonBULLISH 73Earnings
Indivior Delivers Record Q2 Results With 111% EBITDA Growth and Raises Full-Year Outlook
August 3, 2026
Indivior posts a record-breaking second quarter for 2026 marked by 111% EBITDA growth year-over-year, driven by outstanding SUBLOCADE performance and disciplined expense control. The company raises its full-year guidance and positions itself for a proposed merger with Supernus.
7d agoInvesting.com MarketsBULLISH 68M&A
Supernus jumps premarket on merger deal; GameStop drops
Supernus jumps premarket on merger deal; GameStop drops
7d agoReutersBULLISH 58M&A
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →